Sweden· SE-20060713000104
Moxonidin Actavis 0,4 mg Filmdragerad tablett
A moxonidine product containing moxonidine, registered in Sweden by Actavis Group PTC ehf.. The same ATC class is registered in 13 of our 19 countries.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
Where it is registered
Moxonidine is registered in 13 of 19 countries.
Countries holding a registration under ATC C02AC05 (moxonidine), each read from that country’s own register.
- This record: Sweden, from Swedish Medical Products Agency (Sweden)
- 8 of them publish a price we can compare per daily dose
Moxonidine · ATC C02AC05
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of moxonidine costs, country by country.
Normalised to the WHO defined daily dose (0.3 mg), the median price runs from $0.19 in France to $0.70 in Switzerland — a ×3.7 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Moxonidine · price per daily dose (0.3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.70
- IT Italy$0.35
- FR France$0.19
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Moxonidine
- Manufacturer
- Actavis Group PTC ehf.
- Country
- Sweden (SE)
- ATC code
- C02AC05
- ATC class
- Moxonidine
- Defined daily dose
- 0.3 mg, O
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20060713000104
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Moxonidine in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCYNTVIATRIS HEALTHCARE LIMITED, Dublin
- FinlandMoxonidin EpipharmEpipharm Oy
- BelgiumMoxon 0.4 mgViatris
- PolandPhysiotens 0,4Delfarma Sp. z o.o.
- FranceMOXONIDINE BIOGARAN 0,4 mg, comprimé pelliculéBIOGARAN
- NetherlandsMoxamar 0,4 mg, filmomhulde tablettenTeva Pharma B.V.
- ItalyFISIOTENSVIATRIS ITALIA S.R.L.
- NorwayMoxonidin ActavisActavis Group PTC ehf (1)
Authorised across Europe · EMA
The same active substance is authorised in 27 EEA countries. Names it is sold under:
- Austria · Moxonibene, Moxonidin Stada
- Belgium · Moxonidine Eg, Moxonidine Sandoz
- Bulgaria · Moxotens, Moксотенс
- Cyprus · Physiotens, Tarwoxin
- Czechia · Cynt, Moxonidin Actavis
- Germany · Moxogamma, Moxonidin 1 A Pharma
- Denmark · Moxonat, Moxonidin Teva
- Estonia · Moxogamma, Moxonidin Actavis
- Spain · Moxon
- Finland · Moxonidin Ratiopharm, Moxonidin Stada
- France · Moxonidine Biogaran, Moxonidine Eg
- United Kingdom (Northern Ireland) · Moxonidine, Moxonidine Generics [uk]
- Greece · Cynt, Fisiotens
- Croatia · Cynt, Moksonidin Belupo
- Hungary · Moxogamma, Moxonidin Ratiopharm
- Italy · Fisiotens, Moxonidina Eg
- Lithuania · Moxogamma, Moxonidin Hexal
- Luxembourg · Moxonidine Eg, Moxonidine Viatris
- Latvia · Moxogamma, Moxonidin Actavis
- Malta · Physiotens
- Netherlands · Moxamar, Moxonidine Pch
- Norway · Moxonidin Actavis, Physiotens
- Poland · Physiotens
- Portugal · Moxon
- Romania · Physiotens
- Slovenia · Filmsko Obložene Tablete, Moxogamma, Moxogamma
- Slovakia · Moxogamma, Moxonidin Ratiopharm
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5186c4c9-26b0-4a5b-8778-94440d38abd8 GET /v1/drugs/5186c4c9-26b0-4a5b-8778-94440d38abd8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"SmPC",
"PL"
],
"se_npl_id": "20060713000104",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20060713000104",
"product_doc_link": "https://docetp.mpa.se/LMF/Moxonidin%20Actavis%20film-coated%20tablet%20SmPC_09001bee807a66f6.pdf"
}See everything about moxonidine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.